Protagonist Therapeutics Restructures Takeda Partnership for Rusfertide | Boston Capital Investment Club posted on the topic | LinkedIn Major BD Reset: Protagonist Therapeutics Restructures Takeda Partnership Around Rusfertide A significant partnership restructuring has just taken place in the hematology space. Protagonist Therapeuti...

Major BD Reset: Protagonist Therapeutics Restructures Takeda Partnership Around Rusfertide

A significant partnership restructuring has just taken place in the hematology space.

www.linkedin.com/posts/boston...
#BCIC #Biotech #Takeda #ProtagonistTherapeutics #Rusfertide #Hematology #PharmaDeals

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Sun Pharma Eyes $OGN in India's Biggest Pharma Deal Ever
India's Sun Pharma eyes Organon & Co in massive $OGN acquisition
#PharmaDeals #MergersAndAcquisitions #IndianPharmaGiants

http://zip1.io/uJS7Oe

Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere

Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere. #pharmadeals #pharmanews
pharmaphorum.com/news/ipsen-l...

🏆 Pfizer just beat Novo Nordisk in a $10B showdown for Metsera, one of the fiercest pharma battles since the race for COVID vaccines. The deal gives Pfizer a new shot at dominating the booming obesity drug market.

🔗 t.ly/zDK0p
#Pfizer #NovoNordisk #Metsera #PharmaDeals #ObesityDrugs

These agreements boost access for ~40M gov-insured Americans & millions more paying cash. 🌍 Prices effective by Jan for cash, mid-2026 for Medicare. Lilly also cuts diabetes med prices 50-60%. 💡 #AccessToCare #PharmaDeals

Largest acquisitions in the biotech industry in 2025 https://ow.ly/Z6qY50Xg5CG #Biotech #LifeSciences #PharmaDeals

Largest acquisitions in the biotech industry in 2025 https://ow.ly/FFxf50Xg5Cx #Biotech #LifeSciences #PharmaDeals

AstraZeneca Reaches Deal With Trump Administration to Lower U.S. Drug Prices AstraZeneca Agrees to Price Reductions Under U.S. Drug Pricing Plan Published: October 13, 2025, 22:10 EDT AstraZeneca has reached an

AstraZeneca cuts U.S. drug prices in landmark deal with Trump administration.

#USPolitics #DrugPrices #HealthcarePolicy #PharmaDeals #TrumpAdministration

AstraZeneca’s $555m Algen bet: why the pharma giant is buying AI-generated targets, not equity - Biotech Industry Examiner AstraZeneca has inked a deal worth “up to” $555 million with San-Francisco startup Algen Biotechnologies to mine new immunology targets using AI-guided CRISPR

Causality > code. #AstraZeneca’s $555m #Algen deal skips the cap table to pay for validated targets. We decode the strategy.
👉 biotech.industryexaminer.com/astrazeneca-...

#PharmaDeals #Immunology #AI #Biotech #TechNews

mycare.de: Ihre günstige Online-Apotheke in Deutschland In Ihrer Online-Apotheke günstige Medikamente finden: ✓ 20 Jahre Erfahrung ✓ versandkostenfrei ab 29 € ✓ E-Rezepte ✓ TÜV-zertifiziert ► Jetzt bestellen!

💊 Save big on pharmacy essentials! From skincare heroes to allergy relief & chronic care, mycare.de delivers expertise + convenience. Use exclusive coupons → gutschein.coupert.com/store/mycare.de 🎁 Free shipping, custom pill packs & pro advice included! #SaveWithCoupert #PharmaDeals #HealthHacks

Roche to buy 89bio in $3.5bn deal Roche has agreed to acquire 89bio for up to $3.5bn. The deal gives the Swiss drugmaker access to 89bio’s late-stage FGF21 therapy pegozafermin, positioning Roche to expand in liver disease and cardiometabolic treatments. The agreement includes cash and contingent value rights tied to future milestones.

Roche will acquire 89bio in a deal worth up to $3.5bn, adding Phase 3 liver drug pegozafermin to its pipeline. #Biotech #PharmaDeals

Lab to label? Not always.
BioNTech sold a cancer drug to BMS for $11B—originally bought from China’s Biotheus for $800M.
Early exit, or a system that leaves no better choice?
#ChinaBiotech #PharmaDeals #Econsky

#Speaker | Don’t miss Karen Wagner at #SwissHLG today at 13:35 !

🎤 "Managing a portfolio of minority stakes – the view from venture capital"

#VC #Biotech #PharmaDeals #LifeSciences

💼💊 Master Biopharma Valuation!
Learn how to value early-stage compounds, forecast revenue & structure royalty deals like a pro.
📈 Perfect for BD & strategy pros in biotech & pharma.

🔗 zurl.co/0xtXc
#Biopharma #Valuation #RoyedTraining #PharmaDeals #Biotech

JP Morgan Healthcare Conference: J&J, Eli Lilly, and GSK Spark M&A Revival in 2025 The financial hub of San Francisco buzzed with anticipation as the prestigious JP Morgan Healthcare Conference unfolded, setting the stage for a series of transformative announcements that could resha...

www.linkedin.com/pulse/jp-mor...

JP Morgan Healthcare Conference: J&J, Eli Lilly, and GSK Spark M&A Revival in 2025

kstrategyand.com/pharma-news

#HealthcareMergers #PharmaDeals #GSK #MergersAndAcquisitions #BiotechNews #Neuroscience #Oncology #Healthcare2025 #Humanteconomy #Humantec #KStrategyand